36 results on '"Dander E."'
Search Results
2. In nostro fantastico sistema immuntario
- Author
-
Bonecchi, R., Brembilla, N., Canevari, S., Carsetti, R., Casola, S., Cometa, A., Contento, R., Cossarizza, A., Dander, E., De Berardinis, P., D'Elios, M., Di Bonito, P., Ferlazzo, G., Fraziano, M., Gasparini, C., Italiani, P., Mezzanzanica, D., Morrone, S., Muzio, M., Novelli, Francesco, Paolini, R., Paroli, M., Pellicciotta, I., Piconese, S., Pittoni, P., Prisco, A., Pucillo, C., Ruggiero, G., Sironi, M., Sozzani, S., Triggiani, M., Vecchi, A., and Zocchi, M.
- Published
- 2011
3. The chemerin/CMKLR1 axis regulates intestinal graft-versus-host disease
- Author
-
Erica Dander, Paola Vinci, Stefania Vetrano, Camilla Recordati, Rocco Piazza, Grazia Fazio, Donatella Bardelli, Mattia Bugatti, Francesca Sozio, Andrea Piontini, Sonia Bonanomi, Luca Bertola, Elena Tassistro, Maria Grazia Valsecchi, Stefano Calza, William Vermi, Andrea Biondi, Annalisa Del Prete, Silvano Sozzani, Giovanna D’Amico, Dander, E, Vinci, P, Vetrano, S, Recordati, C, Piazza, R, Fazio, G, Bardelli, D, Bugatti, M, Sozio, F, Piontini, A, Bonanomi, S, Bertola, L, Tassistro, E, Valsecchi, M, Calza, S, Vermi, W, Biondi, A, Del Prete, A, Sozzani, S, and D'Amico, G
- Subjects
immunology ,Chemokine ,Macrophage ,bone marrow transplantation ,chemokines ,General Medicine ,macrophages ,transplantation - Abstract
Gastrointestinal graft-versus-host disease (GvHD) is a major cause of mortality and morbidity following allogeneic bone marrow transplantation (allo-BMT). Chemerin is a chemotactic protein that recruits leukocytes to inflamed tissues by interacting with ChemR23/CMKLR1, a chemotactic receptor expressed by leukocytes, including macrophages. During acute GvHD, chemerin plasma levels were strongly increased in allo-BM-transplanted mice. The role of the chemerin/CMKLR1 axis in GvHD was investigated using Cmklr1-KO mice. WT mice transplanted with an allogeneic graft from Cmklr1-KO donors (t-KO) had worse survival and more severe GvHD. Histological analysis demonstrated that the gastrointestinal tract was the organ mostly affected by GvHD in t-KO mice. The severe colitis of t-KO mice was characterized by massive neutrophil infiltration and tissue damage associated with bacterial translocation and exacerbated inflammation. Similarly, Cmklr1- KO recipient mice showed increased intestinal pathology in both allogeneic transplant and dextran sulfate sodium-induced colitis. Notably, the adoptive transfer of WT monocytes into t-KO mice mitigated GvHD manifestations by decreasing gut inflammation and T cell activation. In patients, higher chemerin serum levels were predictive of GvHD development. Overall, these results suggest that CMKLR1/chemerin may be a protective pathway for the control of intestinal inflammation and tissue damage in GvHD.
- Published
- 2023
4. The Bone Marrow Niche in B-Cell Acute Lymphoblastic Leukemia: The Role of Microenvironment from Pre-Leukemia to Overt Leukemia
- Author
-
Giovanna D'Amico, Chiara Palmi, Erica Dander, Giovanni Cazzaniga, Dander, E, Palmi, C, D'Amico, G, and Cazzaniga, G
- Subjects
0301 basic medicine ,Stromal cell ,QH301-705.5 ,Inflammation ,Context (language use) ,Review ,Biology ,Catalysis ,Inorganic Chemistry ,B-cell acute lymphoblastic leukemia (B-ALL) ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Bone Marrow ,medicine ,Tumor Microenvironment ,Animals ,Humans ,Physical and Theoretical Chemistry ,Stem Cell Niche ,Biology (General) ,Molecular Biology ,QD1-999 ,Spectroscopy ,Tumor microenvironment ,Organic Chemistry ,General Medicine ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Hematopoietic Stem Cells ,microenvironment ,Computer Science Applications ,pre-leukemia ,Haematopoiesis ,Leukemia ,Chemistry ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer research ,Disease Progression ,Bone marrow ,medicine.symptom ,bone marrow (BM) niche - Abstract
Genetic lesions predisposing to pediatric B-cell acute lymphoblastic leukemia (B-ALL) arise in utero, generating a clinically silent pre-leukemic phase. We here reviewed the role of the surrounding bone marrow (BM) microenvironment in the persistence and transformation of pre-leukemic clones into fully leukemic cells. In this context, inflammation has been highlighted as a crucial microenvironmental stimulus able to promote genetic instability, leading to the disease manifestation. Moreover, we focused on the cross-talk between the bulk of leukemic cells with the surrounding microenvironment, which creates a “corrupted” BM malignant niche, unfavorable for healthy hematopoietic precursors. In detail, several cell subsets, including stromal, endothelial cells, osteoblasts and immune cells, composing the peculiar leukemic niche, can actively interact with B-ALL blasts. Through deregulated molecular pathways they are able to influence leukemia development, survival, chemoresistance, migratory and invasive properties. The concept that the pre-leukemic and leukemic cell survival and evolution are strictly dependent both on genetic lesions and on the external signals coming from the microenvironment paves the way to a new idea of dual targeting therapeutic strategy.
- Published
- 2021
5. ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment
- Author
-
Martina Chiu, Laura Galuppo, Giovanna D'Amico, Cecilia Carubbi, Roberta Andreoli, Andrea Biondi, Alessandra Fallati, Erica Dander, Giulia Pozzi, Ovidio Bussolati, Prisco Mirandola, Donatella Bardelli, Saverio Tardito, Giuseppe Taurino, Carmelo Rizzari, Massimiliano G. Bianchi, Chiu, M, Taurino, G, Dander, E, Bardelli, D, Fallati, A, Andreoli, R, Bianchi, M, Carubbi, C, Pozzi, G, Galuppo, L, Mirandola, P, Rizzari, C, Tardito, S, Biondi, A, D'Amico, G, and Bussolati, O
- Subjects
Asparaginase ,Stromal cell ,Chemistry ,Mesenchymal stem cell ,Glutamine secretion ,Bone Marrow Cells ,Mesenchymal Stem Cells ,Hematology ,acute lymphoblastic leukemia ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,asparaginase ,Glutamine ,chemistry.chemical_compound ,medicine.anatomical_structure ,Glutamine synthetase ,mesenchymal stromal cell ,medicine ,Cancer research ,Humans ,Bone marrow ,Asparagine - Abstract
Mechanisms underlying the resistance of acute lymphoblastic leukemia (ALL) blasts to l-asparaginase are still incompletely known. Here we demonstrate that human primary bone marrow mesenchymal stromal cells (MSCs) successfully adapt to l-asparaginase and markedly protect leukemic blasts from the enzyme-dependent cytotoxicity through an amino acid trade-off. ALL blasts synthesize and secrete glutamine, thus increasing extracellular glutamine availability for stromal cells. In turn, MSCs use glutamine, either synthesized through glutamine synthetase (GS) or imported, to produce asparagine, which is then extruded to sustain asparagine-auxotroph leukemic cells. GS inhibition prevents mesenchymal cells adaptation to l-asparaginase, lowers glutamine secretion by ALL blasts, and markedly hinders the protection exerted by MSCs on leukemic cells. The pro-survival amino acid exchange is hindered by the inhibition or silencing of the asparagine efflux transporter SNAT5, which is induced in mesenchymal cells by ALL blasts. Consistently, primary MSCs from ALL patients express higher levels of SNAT5 (P < .05), secrete more asparagine (P < .05), and protect leukemic blasts (P
- Published
- 2021
6. Monocyte-macrophage polarization and recruitment pathways in the tumour microenvironment of B-cell acute lymphoblastic leukaemia
- Author
-
Alessandra Fallati, Oscar Maglia, Giovanna D'Amico, Fabio Pagni, Mariella D'Angiò, Erica Dander, Federica Portale, Giulia Cricrì, Barbara Bottazzi, Fabio Pasqualini, Rita Starace, Lisa Brizzolara, A Mantovani, Chiara Buracchi, Paola Allavena, Gloria Bedini, Maria Grazia Valsecchi, Stefania Gaspari, Franco Locatelli, Andrea Biondi, Tamara Gulic, Daniela Silvestri, Cecilia Garlanda, Dander, E, Fallati, A, Gulic, T, Pagni, F, Gaspari, S, Silvestri, D, Cricri, G, Bedini, G, Portale, F, Buracchi, C, Starace, R, Pasqualini, F, D'Angio, M, Brizzolara, L, Maglia, O, Mantovani, A, Garlanda, C, Valsecchi, M, Locatelli, F, Biondi, A, Bottazzi, B, Allavena, P, and D'Amico, G
- Subjects
Adult ,Male ,Chemokine ,acute lymphoblastic leukaemia ,Adolescent ,CD14 ,chemokines ,macrophage ,Monocytes ,03 medical and health sciences ,0302 clinical medicine ,Antigens, CD ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,medicine ,Human Umbilical Vein Endothelial Cells ,Tumor Microenvironment ,Macrophage ,Humans ,CX3CL1 ,Aged ,bone marrow microenvironment ,biology ,Chemistry ,Monocyte ,Macrophages ,Mesenchymal stem cell ,chemokine ,Hematology ,Middle Aged ,Coculture Techniques ,Neoplasm Proteins ,medicine.anatomical_structure ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,030220 oncology & carcinogenesis ,mesenchymal stromal cell ,monocyte ,Cancer research ,biology.protein ,Female ,Bone marrow ,mesenchymal stromal cells ,CD163 ,030215 immunology - Abstract
B-cell acute lymphoblastic leukaemia (B-ALL) reprograms the surrounding bone marrow (BM) stroma to create a leukaemia-supportive niche. To elucidate the contribution of immune cells to the leukaemic microenvironment, we investigated the involvement of monocyte/macrophage compartments, as well as several recruitment pathways in B-ALL development. Immunohistochemistry analyses showed that CD68-expressing macrophages were increased in leukaemic BM biopsies, compared to controls and predominantly expressed the M2-like markers CD163 and CD206. Furthermore, the "non-classical" CD14+ CD16++ monocyte subset, expressing high CX3CR1 levels, was significantly increased in B-ALL patients' peripheral blood. CX3CL1 was shown to be significantly upregulated in leukaemic BM plasma, thus providing an altered migratory pathway possibly guiding NC monocyte recruitment into the BM. Additionally, the monocyte/macrophage chemoattractant chemokine ligand 2 (CCL2) strongly increased in leukaemic BM plasma, possibly because of the interaction of leukaemic cells with mesenchymal stromal cells and vascular cells and due to a stimulatory effect of leukaemia-related inflammatory mediators. C5a, a macrophage chemoattractant and M2-polarizing factor, further appeared to be upregulated in the leukaemic BM, possibly as an effect of PTX3 decrease, that could unleash complement cascade activation. Overall, deregulated monocyte/macrophage compartments are part of the extensive BM microenvironment remodelling at B-ALL diagnosis and could represent valuable targets for novel treatments to be coupled with classical chemotherapy.
- Published
- 2020
7. Intranasal delivery of mesenchymal stem cell‐derived extracellular vesicles exerts immunomodulatory and neuroprotective effects in a 3xTg model of Alzheimer's disease
- Author
-
Francesca Massenzio, Matteo Pedrazzoli, Claudia D'Agostino, Elena Bresciani, Elena Lonati, Giovanna D'Amico, Laura Rizzi, Antonio Torsello, Mario Rosario Buffelli, Michela Matteoli, Silvia Coco, Mario Mauri, Alessandra Bulbarelli, Chiara A. Elia, Morris Losurdo, Laura Molteni, Erica Dander, Losurdo, Morri, Pedrazzoli, Matteo, D'Agostino, Claudia, Elia, Chiara A., Massenzio, Francesca, Lonati, Elena, Mauri, Mario, Rizzi, Laura, Molteni, Laura, Bresciani, Elena, Dander, Erica, D'Amico, Giovanna, Bulbarelli, Alessandra, Torsello, Antonio, Matteoli, Michela, Buffelli, Mario, Coco, Silvia, Losurdo, M, Pedrazzoli, M, D'Agostino, C, Elia, C, Massenzio, F, Lonati, E, Mauri, M, Rizzi, L, Molteni, L, Bresciani, E, Dander, E, D'Amico, G, Bulbarelli, A, Torsello, A, Matteoli, M, Buffelli, M, and Coco, S
- Subjects
0301 basic medicine ,microglia ,Pharmacology ,0302 clinical medicine ,Tissue‐specific Progenitor and Stem Cells ,Cells, Cultured ,mesenchymal stem cell ,lcsh:R5-920 ,dendritic spine ,Microglia ,lcsh:Cytology ,Microfilament Proteins ,Cell Polarity ,General Medicine ,Alzheimer's disease ,Neuroprotection ,Phenotype ,medicine.anatomical_structure ,Cytokines ,medicine.symptom ,lcsh:Medicine (General) ,extracellular vesicles ,Genetically modified mouse ,Antigens, Differentiation, Myelomonocytic ,Mice, Transgenic ,Inflammation ,Immunomodulation ,03 medical and health sciences ,Alzheimer Disease ,Antigens, CD ,medicine ,Animals ,Humans ,lcsh:QH573-671 ,Administration, Intranasal ,Neuroinflammation ,mesenchymal stem cells ,Innate immune system ,business.industry ,Calcium-Binding Proteins ,Mesenchymal stem cell ,Cell Biology ,dendritic spines ,Microvesicles ,Mice, Inbred C57BL ,Disease Models, Animal ,030104 developmental biology ,inflammation ,extracellular vesicle ,business ,Biomarkers ,030217 neurology & neurosurgery ,Developmental Biology - Abstract
The critical role of neuroinflammation in favoring and accelerating the pathogenic process in Alzheimer's disease (AD) increased the need to target the cerebral innate immune cells as a potential therapeutic strategy to slow down the disease progression. In this scenario, mesenchymal stem cells (MSCs) have risen considerable interest thanks to their immunomodulatory properties, which have been largely ascribed to the release of extracellular vesicles (EVs), namely exosomes and microvesicles. Indeed, the beneficial effects of MSC‐EVs in regulating the inflammatory response have been reported in different AD mouse models, upon chronic intravenous or intracerebroventricular administration. In this study, we use the triple‐transgenic 3xTg mice showing for the first time that the intranasal route of administration of EVs, derived from cytokine‐preconditioned MSCs, was able to induce immunomodulatory and neuroprotective effects in AD. MSC‐EVs reached the brain, where they dampened the activation of microglia cells and increased dendritic spine density. MSC‐EVs polarized in vitro murine primary microglia toward an anti‐inflammatory phenotype suggesting that the neuroprotective effects observed in transgenic mice could result from a positive modulation of the inflammatory status. The possibility to administer MSC‐EVs through a noninvasive route and the demonstration of their anti‐inflammatory efficacy might accelerate the chance of a translational exploitation of MSC‐EVs in AD., In a preclinical model of Alzheimer's disease, characterized by neuronal damage and a high rate of inflammation (left), the intranasal (IN) administration of extracellular vesicles (EVs) derived from mesenchymal stromal/stem cells (MSCs) operates in dampening inflammation (by reducing microglia activation) and in inducing neuroprotective effects (by decreasing spine loss) (right). These data suggest the possibility that the IN route administration of MSC‐EVs might accelerate the chance of a translational exploitation of MSC‐EVs toward therapy.
- Published
- 2020
8. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis
- Author
-
Alice Pievani, Elena Maria Elli, Mara Riminucci, Andrea Biondi, Noemi Di Marzo, Federica Mottadelli, Pietro Pioltelli, Erica Dander, Elisa Diral, Samantha Donsante, Giovanna D'Amico, Giuseppe Isimbaldi, Lucia Cardinale, Marta Serafini, Benedetta Rambaldi, Rambaldi, B, Diral, E, Donsante, S, Di Marzo, N, Mottadelli, F, Cardinale, L, Dander, E, Isimbaldi, G, Pioltelli, P, Biondi, A, Riminucci, M, D'Amico, G, Elli, E, Pievani, A, and Serafini, M
- Subjects
Adult ,Male ,Myeloid ,Stromal cell ,Myeloproliferative neoplasm ,myelofibrosis ,myeloproliferative neoplasms ,Cohort Studies ,03 medical and health sciences ,ActivinA ,0302 clinical medicine ,Polycythemia vera ,Fibrosis ,Bone Marrow ,medicine ,Humans ,Myelofibrosis ,mesenchymal stromal cells ,Polycythemia Vera ,Cells, Cultured ,Aged ,Myeloproliferative Disorders ,Essential thrombocythemia ,business.industry ,Mesenchymal stromal cell ,Mesenchymal stem cell ,Myelofibrosi ,Cell Differentiation ,Mesenchymal Stem Cells ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Activins ,medicine.anatomical_structure ,Primary Myelofibrosis ,030220 oncology & carcinogenesis ,Cancer research ,Female ,Bone marrow ,business ,030215 immunology ,Thrombocythemia, Essential - Abstract
Mesenchymal stromal cells (MSCs) represent an essential component of the bone marrow (BM) niche and display disease-specific alterations in several myeloid malignancies. The aim of this work was to study possible MSC abnormalities in Philadelphia-negative myeloproliferative neoplasms (MPNs) in relationship to the degree of BM fibrosis. MSCs were isolated from BM of 6 healthy donors (HD) and of 23 MPN patients, classified in 3 groups according to the diagnosis and the grade of BM fibrosis: polycythemia vera and essential thrombocythemia (PV/ET), low fibrosis myelofibrosis (LF-MF), and high fibrosis MF (HF-MF). MSC cultures were established from 21 of 23 MPN patients. MPN-derived MSCs did not exhibit any functional impairment in their adipogenic/osteogenic/chondrogenic differentiation potential and displayed a phenotype similar to HD-derived MSCs but with a decreased expression of CD146. All MPN-MSC lines were negative for the patient-specific hematopoietic clone mutations (JAK2, MPL, CALR). MSCs derived from HF-MF patients displayed a reduced clonogenic potential and a lower growth kinetic compared to MSCs from HD, LF-MF, and PV/ET patients. mRNA levels of hematopoiesis regulatory molecules were unaffected in MSCs from HF-MF compared to HD. Finally, in vitro ActivinA secretion by MSCs was increased in HF-MF compared to LF-MF patients, in association with a lower hemoglobin value. Increased ActivinA immunolabeling on stromal cells and erythroid precursors was also observed in HF-MF BM biopsies. In conclusion, higher grade of BM fibrosis is associated with functional impairment of MSCs and the increased secretion of ActivinA may represent a suitable target for anemia treatment in MF patients.
- Published
- 2020
9. ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells
- Author
-
Monica Lupi, Daniela Silvestri, Giovanna D'Amico, Maria Grazia Valsecchi, Geertruy te Kronnie, Barbara Russo, Fabio Pagni, Franco Locatelli, Patrizia Vergani, Carmelo Rizzari, Andrea Biondi, Noemi Marino, Federica Portale, Giulia Cricrì, Stefania Gaspari, Silvia Bresolin, Paolo Ubezio, Erica Dander, Portale, F, Cricrì, G, Bresolin, S, Lupi, M, Gaspari, S, Silvestri, D, Russo, B, Marino, N, Ubezio, P, Pagni, F, Vergani, P, Te Kronnie, G, Valsecchi, M, Locatelli, F, Rizzari, C, Biondi, A, Dander, E, and D'Amico, G
- Subjects
Stromal cell ,CD34 ,Bone Marrow Cells ,Biology ,Article ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Bone Marrow ,Cell Movement ,Cell Line, Tumor ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,Biomarkers, Tumor ,medicine ,Animals ,Humans ,Pediatric Acute Lymphoblastic Leukemia ,B cell ,Cell Proliferation ,Gene Expression Regulation, Leukemic ,Mesenchymal stem cell ,activinA ,precursor B-cell ,acute lymphoblastic leukemia ,Mesenchymal Stem Cells ,Hematology ,Acute Lymphoblastic Leukemia ,medicine.disease ,Activins ,Bone Marrow Microenvironment ,Disease Models, Animal ,Haematopoiesis ,Leukemia ,Mesenchymal Stem Cell ,medicine.anatomical_structure ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Cell culture ,Cancer research ,Cytokines ,Bone marrow ,Inflammation Mediators ,Stromal Cells ,ALL ,030215 immunology - Abstract
B-cell precursor-acute lymphoblastic leukemia modulates the bone marrow (BM) niche to become leukemia-supporting and chemo-protective by reprogramming the stromal microenvironment. New therapies targeting the interplay between leukemia and stroma can help improve disease outcome. We identified ActivinA, a TGF-b family member with a well-described role in promoting several solid malignancies, as a factor favoring leukemia that could represent a new potential target for therapy. ActivinA resulted over-expressed in the leukemic BM and its production was strongly induced in mesenchymal stromal cells after culture with leukemic cells. Moreover, MSCs isolated from BM of leukemic patients showed an intrinsic ability to secrete higher amounts of ActivinA compared to their normal counterparts. The pro-inflammatory leukemic BM microenvironment synergized with leukemic cells to induce stromal-derived ActivinA. Gene expression analysis of ActivinA-treated leukemic cells showed that this protein was able to significantly influence motility-associated pathways. Interestingly, ActivinA promoted random motility and CXCL12-driven migration of leukemic cells, even at suboptimal chemokine concentrations, characterizing the leukemic niche. Conversely, ActivinA severely impaired CXCL12-induced migration of healthy CD34 + cells. This opposite effect can be explained by the ability of ActivinA to increase intracellular calcium only in leukemic cells, boosting cytoskeleton dynamics through a higher rate of actin polymerization. Moreover, by stimulating the invasiveness of the leukemic cells, ActivinA was found to be a leukemia-promoting factor. Importantly, the ability of ActivinA to enhance BM engraftment and the metastatic potential of leukemic cells was confirmed in a xenograft mouse model of the disease. Overall, ActivinA was seen to be a key factor in conferring a migratory advantage to leukemic cells over healthy hematopoiesis within the leukemic niche.
- Published
- 2018
10. Mesenchymal stromal cells from Shwachman-Diamond syndrome patients fail to recreate a bone marrow nichein vivoand exhibit impaired angiogenesis
- Author
-
Alice Pievani, Claudia Cappuzzello, Erica Dander, Carlo Dufour, Giovanna D'Amico, Paolo Pierani, Marco Cipolli, Simone Cesaro, Cristina Bugarin, Andrea Biondi, Paola Corti, Piero Farruggia, Donatella Bardelli, Grazia Fazio, Bardelli, D, Dander, E, Bugarin, C, Cappuzzello, C, Pievani, A, Fazio, G, Pierani, P, Corti, P, Farruggia, P, Dufour, C, Cesaro, S, Cipolli, M, Biondi, A, and D'Amico, G
- Subjects
Male ,0301 basic medicine ,Angiogenesis ,Mice, SCID ,angiogenesis ,Bone Marrow ,Lipomatosis ,Medicine ,Child ,Bone Marrow Diseases ,Cells, Cultured ,Shwachman–Diamond syndrome ,Hematology ,Cell Differentiation ,Shwachman-Diamond Syndrome ,Vascular endothelial growth factor A ,Haematopoiesis ,medicine.anatomical_structure ,Child, Preschool ,mesenchymal stromal cell ,Heterografts ,Female ,mesenchymal stromal cells ,Shwachman-Diamond syndrome ,bone marrow niche ,childhood ,Chondrogenesis ,Adult ,medicine.medical_specialty ,Adolescent ,Neovascularization, Physiologic ,Bone Marrow Cells ,Young Adult ,03 medical and health sciences ,Chondrocytes ,Internal medicine ,Animals ,Humans ,business.industry ,Mesenchymal stem cell ,Bone marrow failure ,angiogenesi ,Infant ,Mesenchymal Stem Cells ,medicine.disease ,Hematopoiesis ,Cartilage ,030104 developmental biology ,Cancer research ,Exocrine Pancreatic Insufficiency ,Bone marrow ,business - Abstract
Shwachman-Diamond syndrome (SDS) is a rare multi-organ recessive disease mainly characterised by pancreatic insufficiency, skeletal defects, short stature and bone marrow failure (BMF). As in many other BMF syndromes, SDS patients are predisposed to develop a number of haematopoietic malignancies, particularly myelodysplastic syndrome and acute myeloid leukaemia. However, the mechanism of cancer predisposition in SDS patients is only partially understood. In light of the emerging role of mesenchymal stromal cells (MSCs) in the regulation of bone marrow homeostasis, we assessed the ability of MSCs derived from SDS patients (SDS-MSCs) to recreate a functional bone marrow niche, taking advantage of a murine heterotopic MSC transplant model. We show that the ability of semi-cartilaginous pellets (SCPs) derived from SDS-MSCs to generate complete heterotopic ossicles in vivo is severely impaired in comparison with HD-MSC-derived SCPs. Specifically, after in vitro angiogenic stimuli, SDS-MSCs showed a defective ability to form correct networks, capillary tubes and vessels and displayed a marked decrease in VEGFA expression. Altogether, these findings unveil a novel mechanism of SDS-mediated haematopoietic dysfunction based on hampered ability of SDS-MSCs to support angiogenesis. Overall, MSCs could represent a new appealing therapeutic target to treat dysfunctional haematopoiesis in paediatric SDS patients.
- Published
- 2018
11. Mesenchymal stromal cell-secreted chemerin is a novel immunomodulatory molecule driving the migration of ChemR23-expressing cells
- Author
-
Antonio Bastone, Annalisa Del Prete, Silvia Schiarea, Giovanna D'Amico, Andrea Biondi, Paola Vinci, Claudia Cappuzzello, Erica Dander, Vinci, P, Bastone, A, Schiarea, S, Cappuzzello, C, Del Prete, A, Dander, E, Biondi, A, and D'Amico, G
- Subjects
0301 basic medicine ,Blood Platelets ,Cell Extracts ,Proteases ,Cancer Research ,Stromal cell ,Immunology ,Cell Culture Techniques ,CMKLR1 ,Mesenchymal Stem Cell Transplantation ,Proinflammatory cytokine ,Immunomodulation ,03 medical and health sciences ,Human Umbilical Vein Endothelial Cells ,Chemerin ,Humans ,Immunology and Allergy ,Cells, Cultured ,ChemR23 receptor ,Genetics (clinical) ,Inflammation ,Transplantation ,biology ,Mesenchymal stromal cell ,Chemotaxis ,Mesenchymal stem cell ,Chimerin Proteins ,Mesenchymal Stem Cells ,Cell Biology ,Cell biology ,Culture Media ,030104 developmental biology ,Oncology ,biology.protein ,Platelet lysate ,Receptors, Chemokine ,Fetal bovine serum - Abstract
Background Mesenchymal stromal cells (MSCs) are multipotent cells characterized by broad immunomodulatory properties exploited for the treatment of inflammatory disorders. However, the efficacy of MSC-based therapy is highly variable and tightly linked to MSC culture conditions and treatment schedule. Thus, the identification of novel key molecules regulating MSC immunomodulatory activities in vivo might constitute a crucial step toward the optimization of currently available clinical protocols. In this regard, herein, we sought to determine whether the newly identified chemotactic protein, chemerin, plays a role in MSC-mediated regulation of inflammation. Methods Chemerin production by human MSCs was investigated under different culture conditions using enzyme-linked immunosorbent assay (ELISA). After purification, MSC-secreted chemerin was identified using mass spectrometry analysis and the biological activity of secreted isoforms was evaluated using migration assay. Results Bone marrow–derived MSCs secrete chemerin and express its receptors ChemR23 and CCRL2. Chemerin production is dependent on culture conditions and increases upon stimulation with inflammatory cytokines. In particular, platelet lysate (PL)-MSCs produce higher levels of chemerin compared with fetal bovine serum (FBS)-MSCs. Furthermore, chemerin is secreted by MSCs as an inactive precursor, which can be converted into its active form by exogenous chemerin-activating serine and cysteine proteases. Discussion Our data indicate that, in response to various inflammatory stimuli, MSCs secrete high amounts of inactive chemerin, which can then be activated by inflammation-induced tissue proteases. In light of these initial findings, we propose that further analysis of chemerin functions in vivo might constitute a crucial step toward optimizing MSC-based therapy for inflammatory diseases.
- Published
- 2017
12. Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients
- Author
-
Francesca Masciocchi, Attilio Rovelli, Giovanna D'Amico, Sergio Cortelazzo, Adriana Balduzzi, Anna Grassi, Ettore Biagi, Martino Introna, Olga Pedrini, Giovanna Lucchini, Paolo Perseghin, Andrea Biondi, Giuseppe Gaipa, Daniela Longoni, Chiara Capelli, Stefania Galimberti, Erica Dander, Enrico Maria Pogliani, Fabio Pavan, Irene Cavattoni, Matteo Parma, Sara Deola, Josée Golay, Alessandra Algarotti, Daniela Belotti, Caterina Micò, Alessandro Rambaldi, Introna, M, Lucchini, G, Dander, E, Galimberti, S, Rovelli, A, Balduzzi, A, Longoni, D, Pavan, F, Masciocchi, F, Algarotti, A, Micò, C, Grassi, A, Deola, S, Cavattoni, I, Gaipa, G, Belotti, D, Perseghin, P, Parma, M, Pogliani, E, Golay, J, Pedrini, O, Capelli, C, Cortelazzo, S, D'Amico, G, Biondi, A, Rambaldi, A, and Biagi, E
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Mesenchymal stromal cells ,Graft vs Host Disease ,Antineoplastic Agents ,Disease ,Mesenchymal Stem Cell Transplantation ,Severity of Illness Index ,Gastroenterology ,Steroid refractory graft-versus-host disease (GVHD) ,Cell therapy ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Child ,Adverse effect ,Aged ,Transplantation ,Mesenchymal stromal cell ,business.industry ,Remission Induction ,Mesenchymal stem cell ,Infant ,Immunosuppression ,Hematology ,Middle Aged ,medicine.disease ,Survival Analysis ,Acute toxicity ,Immunosuppressive treatment ,Surgery ,Graft-versus-host disease ,Drug Resistance, Neoplasm ,Child, Preschool ,Hematologic Neoplasms ,Hematopoietic stem cell transplantation (HSCT) ,Female ,Steroids ,Platelet lysate ,business ,Immunosuppressive Agents - Abstract
This phase I multicenter study was aimed at assessing the feasibility and safety of intravenous administration of third party bone marrow–derived mesenchymal stromal cells (MSC) expanded in platelet lysate in 40 patients (15 children and 25 adults), experiencing steroid-resistant grade II to IV graft-versus-host disease (GVHD). Patients received a median of 3 MSC infusions after having failed conventional immunosuppressive therapy. A median cell dose of 1.5 × 106/kg per infusion was administered. No acute toxicity was reported. Overall, 86 adverse events and serious adverse events were reported in the study, most of which (72.1%) were of infectious nature. Overall response rate, measured at 28 days after the last MSC injection, was 67.5%, with 27.5% complete response. The latter was significantly more frequent in patients exhibiting grade II GVHD as compared with higher grades (61.5% versus 11.1%, P = .002) and was borderline significant in children as compared with adults (46.7 versus 16.0%, P = .065). Overall survival at 1 and 2 years from the first MSC administration was 50.0% and 38.6%, with a median survival time of 1.1 years. In conclusion, MSC can be safely administered on top of conventional immunosuppression for steroid resistant GVHD treatment. Eudract Number 2008-007869-23, NCT01764100.
- Published
- 2014
13. Activin A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia
- Author
-
Andrea Biondi, Linda Beneforti, Alessandra Fallati, Giovanna D'Amico, Chiara Palmi, Erica Dander, Federica Portale, Giovanni Cazzaniga, Portale, F, Beneforti, L, Fallati, A, Biondi, A, Palmi, C, Cazzaniga, G, Dander, E, and D'Amico, G
- Subjects
0301 basic medicine ,Cancer Research ,Stromal cell ,Oncogene Proteins, Fusion ,MED/03 - GENETICA MEDICA ,Chromosomes, Human, Pair 21 ,Clone (cell biology) ,Biology ,Translocation, Genetic ,Cell Line ,03 medical and health sciences ,0302 clinical medicine ,Genetic ,Bone Marrow ,hemic and lymphatic diseases ,Genetics ,medicine ,Humans ,Stem Cell Niche ,Molecular Biology ,Progenitor ,Chromosomes, Human, Pair 12 ,Leukemia ,Mesenchymal stem cell ,Mesenchymal Stem Cells ,Cell Biology ,Hematology ,medicine.disease ,Chemokine CXCL12 ,Activins ,Cell biology ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Core Binding Factor Alpha 2 Subunit ,Bone marrow ,Stem cell ,Precancerous Conditions ,Transforming growth factor - Abstract
The TEL-AML1 fusion gene, generated by the t(12;21) chromosome translocation, arises in a progenitor/stem cell and could induce clonal expansion of a persistent preleukemic B-cell clone which, on acquisition of secondary alterations, may turn into full-blown leukemia. During infections, deregulated cytokine signaling, including transforming growth factor β (TGF-β), can further accelerate this process by creating a protumoral bone marrow (BM) microenvironment. Here, we show that activin A, a member of the TGF-β family induced under inflammatory conditions, inhibits the proliferation of normal progenitor B cells but not that of preleukemic TEL-AML1-positive clones, thereby providing a selective advantage to the latter. Finally, we find that activin A inhibits BM-derived mesenchymal stromal cell-mediated secretion of CXCL12, a major chemoattractant in the BM compartment, thereby contributing to shape a leukemia-promoting environment. Overall, our findings indicate that activin A, in concert with TGF-β, could play an important role in the creation of a pro-oncogenic BM microenvironment and provide novel mechanistic insights into TEL-AML1-associated leukemogenesis.
- Published
- 2019
14. The Effects of Propofol and Ketamine on the Cytokine Levels of Children With Acute Lymphoblastic Leukemia
- Author
-
Riccardo Stucchi, Erica Dander, Giovanna D'Amico, Gianluca Bertolizio, Pablo Ingelmo, Emre Sahillioglu, Momcilo Jankovic, Andrea Biondi, Marta Somaini, Bertolizio, G, Stucchi, R, Sahillioglu, E, Somaini, M, Dander, E, Biondi, A, Jankovic, M, D'Amico, G, and Ingelmo, P
- Subjects
Chemotherapy ,medicine.diagnostic_test ,business.industry ,Lumbar puncture ,Sedation ,medicine.medical_treatment ,Hematology ,Proinflammatory cytokine ,Oncology ,children, cytokines, ketamine, propofol, sedation ,Concomitant ,Anesthesia ,Pediatrics, Perinatology and Child Health ,medicine ,Ketamine ,Methotrexate ,medicine.symptom ,Propofol ,business ,medicine.drug - Abstract
The immune system of children with acute lymphoblastic leukemia (ALL) is affected by both the underlying disease and the chemotherapy. Children with ALL receive sedation for diagnostic and therapeutic procedures, which may contribute to immune competence alteration. The effects of propofol-ketamine combination on the immune system of children with ALL have not been investigated. This cohort study was designed to assess the immunomodulatory activity of the propofol-ketamine combination on proinflammatory and anti-inflammatory cytokines of children with ALL undergoing painful procedures. We enrolled 20 children with ALL undergoing bone marrow aspiration (BMA) and lumbar puncture with methotrexate. All children received sedation with IV ketamine (0.5 mg/kg) and propofol (3±2 mg/kg). Plasma concentration of cytokines interleukin (IL)-1β, IL-2, IL-6, IL-10, IL-8, IL-12p70, and interferon-γ before sedation for BMA was represented as T0, during lumbar puncture with methotrexate sedation 6 hours after T0 was represented as T1, and 24 hours after BMA was represented as T2. Sedation with propofol-ketamine combination did not modify the plasma concentration of the most measured cytokines and the T helper 1/2 ratio in children with ALL. There was a significant reduction in IL-8 concentration 24 hours after BMA associated with the concomitant administration of steroids and methotrexate. These data suggest that sedation with propofol-ketamine combination may not affect the immediate outcome of children with ALL. Copyright © 2013 by Lippincott Williams & Wilkins.
- Published
- 2013
15. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation
- Author
-
Claudia Cappuzzello, Erica Dander, Roberto Leone, Andrea Biondi, Attilio Rovelli, Fabio Pasqualini, Paola Quarello, Matteo Parma, Fabio Pagni, Fabio Pavan, Paola De Lorenzo, Barbara Bottazzi, Cecilia Garlanda, Giovanna D'Amico, Franco Locatelli, Sonia Bonanomi, Giovanni Salvatori, Paola Vinci, Marina Sironi, Ivan Cuccovillo, Alberto Mantovani, Maria Grazia Valsecchi, Francesca Masciocchi, Franca Fagioli, Adriana Balduzzi, Elisabetta Terruzzi, Giulia Prunotto, Dander, E, Lorenzo, P, Bottazzi, B, Quarello, P, Vinci, P, Balduzzi, A, Masciocchi, F, Bonanomi, S, Cappuzzello, C, Prunotto, G, Pavan, F, Pasqualini, F, Sironi, M, Cuccovillo, I, Leone, R, Salvatori, G, Parma, M, Terruzzi, E, Pagni, F, Locatelli, F, Mantovani, A, Fagioli, F, Biondi, A, Garlanda, C, Valsecchi, M, Rovelli, A, and D'Amico, G
- Subjects
0301 basic medicine ,Male ,Time Factors ,medicine.medical_treatment ,Drug Resistance ,Graft vs Host Disease ,Hematopoietic stem cell transplantation ,Disease ,Inbred C57BL ,Gastroenterology ,Severity of Illness Index ,Mice ,Adrenal Cortex Hormones ,Prospective Studies ,Child ,Inbred BALB C ,Mice, Inbred BALB C ,Hematology ,biology ,Research Paper: Immunology ,Age Factors ,Hematopoietic Stem Cell Transplantation ,Up-Regulation ,Serum Amyloid P-Component ,surgical procedures, operative ,C-Reactive Protein ,Treatment Outcome ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Italy ,Oncology ,Pediatric haematopoietic stem cell transplantation ,Child, Preschool ,Biomarker (medicine) ,Female ,Immunology and microbiology section ,Homologous ,medicine.medical_specialty ,Adolescent ,Acute graft-versus-host disease ,Biomarkers ,Immune response ,Immunity ,Pentraxin 3 (PTX3) ,Animals ,Disease Models, Animal ,Humans ,Mice, Inbred C57BL ,Predictive Value of Tests ,Transplantation, Homologous ,Young Adult ,03 medical and health sciences ,Internal medicine ,Severity of illness ,medicine ,Preschool ,Transplantation ,business.industry ,Animal ,C-reactive protein ,acute graft-versus-host disease ,biomarkers ,hematology ,immune response ,immunity ,immunology and microbiology section ,pediatric haematopoietic stem cell transplantation ,pentraxin 3 (PTX3) ,Biomarker ,medicine.disease ,030104 developmental biology ,Graft-versus-host disease ,Immunology ,Disease Models ,biology.protein ,business - Abstract
Acute Graft-versus-Host Disease (GvHD) remains a major complication of allogeneic haematopoietic stem cell transplantation, with a significant proportion of patients failing to respond to first-line systemic corticosteroids. Reliable biomarkers predicting disease severity and response to treatment are warranted to improve its management. Thus, we sought to determine whether pentraxin 3 (PTX3), an acute-phase protein produced locally at the site of inflammation, could represent a novel acute GvHD biomarker. Using a murine model of the disease, we found increased PTX3 plasma levels after irradiation and at GvHD onset. Similarly, plasma PTX3 was enhanced in 115 pediatric patients on day of transplantation, likely due to conditioning, and at GvHD onset in patients experiencing clinical symptoms of the disease. PTX3 was also found increased in skin and colon biopsies from patients with active disease. Furthermore, PTX3 plasma levels at GvHD onset were predictive of disease outcome since they resulted significantly higher in both severe and therapy-unresponsive patients. Multiple injections of rhPTX3 in the murine model of GvHD did not influence the disease course. Taken together, our results indicate that PTX3 constitutes a biomarker of GvHD severity and therapy response useful to tailor treatment intensity according to early risk-stratification of GvHD patients.
- Published
- 2016
16. Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population
- Author
-
Giovanna D'Amico, Maria Grazia Orofino, J. Golay, Daniela Belotti, Ettore Biagi, Martino Introna, Giuseppe Gaipa, Paolo Perseghin, Attilio Rovelli, Andrea Biondi, Giovanna Lucchini, Sonia Bonanomi, Sarah Marktel, Patrizia Chiusolo, Paola Vinci, Edoardo Lanino, Erica Dander, Alessandro Rambaldi, Agnese Salvadè, Chiara Capelli, Adriana Balduzzi, Lucchini, G, Introna, M, Dander, E, Rovelli, A, Balduzzi, A, Bonanomi, S, Salvadè, A, Capelli, C, Belotti, D, Gaipa, G, Perseghin, P, Vinci, P, Lanino, E, Chiusolo, P, Orofino, M, Marktel, S, Golay, J, Rambaldi, A, Biondi, A, D'Amico, G, and Biagi, E
- Subjects
Blood Platelets ,Compassionate Use Trials ,Male ,medicine.medical_specialty ,Adolescent ,Bone marrow transplantation ,medicine.medical_treatment ,Mesenchymal stromal cells ,GVHD ,Graft vs Host Disease ,Salvage therapy ,Mesenchymal Stem Cell Transplantation ,Gastroenterology ,Cell therapy ,immune system diseases ,Internal medicine ,medicine ,Humans ,Child ,Salvage Therapy ,Transplantation ,Mesenchymal stromal cell ,business.industry ,Mesenchymal stem cell ,Mesenchymal Stem Cells ,Immunosuppression ,Hematology ,medicine.disease ,Surgery ,surgical procedures, operative ,Graft-versus-host disease ,Child, Preschool ,Cord blood ,Female ,Platelet lysate ,Stromal Cells ,business - Abstract
Despite advances in graft-versus-host-disease (GVHD) treatment, it is estimated that overall survival (OS) at 2 years for hematopoietic cell transplantation (HCT) recipients who experience steroid-resistant GVHD is 10%. Among recent therapeutic approaches for GVHD treatment, mesenchymal stromal cells (MSCs) hold a key position. We describe a multicenter experience of 11 pediatric patients diagnosed with acute or chronic GVHD (aGVHD, cGVHD) treated for compassionate use with GMP-grade unrelated HLA-disparate donors' bone marrow-derived MSCs, expanded in platelet-lysate (PL)-containing medium. Eleven patients (aged 4-15 years) received intravenous (i.v.) MSCs for aGVHD or cGVHD, which was resistant to multiple lines of immunosuppression. The median dose was 1.2 x 10(6)/kg (range: 0.7-3.7 x 10(6)/kg). No acute side effects were observed, and no late side effects were reported at a median follow-up of 8 months (range: 4-18 months). Overall response was obtained in 71.4% of patients, with complete response in 23.8% of cases. None of our patients presented GVHD progression upon MSC administration, but 4 patients presented GVHD recurrence 2 to 5 months after infusion. Two patients developed chronic limited GVHD. This study underlines the safety of PL-expanded MSC use in children. MSC efficacy seems to be greater in aGVHD than in cGVHD, even after failure of multiple lines of immunosuppression.
- Published
- 2010
17. Regulatory T Cells and Extracorporeal Photochemotherapy: Correlation With Clinical Response and Decreased Frequency of Proinflammatory T Cells
- Author
-
Ettore Biagi, Paolo Perseghin, Cristina Bugarin, Erica Dander, Giuseppe Gaipa, Adriana Balduzzi, Lucia Di Maio, Andrea Biondi, Iolanda Di Biaso, Matteo Parma, Giovanna D'Amico, Di Biaso, I, DI MAIO, L, Bugarin, C, Gaipa, G, Dander, E, Balduzzi, A, Parma, M, D'Amico, G, Perseghin, P, Biondi, A, and Biagi, E
- Subjects
T-Lymphocytes ,Population ,Graft vs Host Disease ,chemical and pharmacologic phenomena ,Inflammation ,T-Lymphocytes, Regulatory ,Proinflammatory cytokine ,Immune system ,immune system diseases ,Humans ,Medicine ,ECP, regulatory T cells, HSCT ,IL-2 receptor ,education ,Transplantation ,education.field_of_study ,business.industry ,ELISPOT ,FOXP3 ,Interleukin ,hemic and immune systems ,Photopheresis ,Immunology ,Methoxsalen ,medicine.symptom ,business - Abstract
Background. Immune mechanisms of extracorporeal photochernotherapy (ECP) in refractory/resistant graft-versus-host disease (GvHD) are complex. We have previously analyzed the role of CD4(+)CD25(+)Foxp3(+) regulatory T cells (T-regs). Methods. In the current study, we have enlarged the size of the population (n=27; chronic GvHD=18, acute GvHD=9) for a median follow-up of 24 months. T-regs were monitored for CD4, CD25, glucocorticoid-induced tumor necrosis factor receptor (GITR), CD62L, CCR7, Foxp3, and STAT-5. Immune analysis by interleukin (IL)-17 Elispot was carried out on circulating T-helper CD4(+) cells secreting IL-17, a subset of T cells considered relevant in the pathogenesis of GvHD. Results. We confirm that ECP is accompanied by a significant increase of CD4(+)CD25(+)Foxp3(+)GITR(+)CD62L(+)CCR7(+) T-regs. Sorted T-regs show augmented phosphorylation of STAT-5. Only ECP-responding patients demonstrate a raise of circulating T-regs, being mostly affected by chronic GvHD. Moreover, this phenomenon corresponds to a diminished secretion of IL-17. Discussion. In conclusion, our study shows that T-regs represent important immune mediators of the clinical benefits of ECP in patients affected by GvHD.
- Published
- 2009
18. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex
- Author
-
Giuseppe Gerna, Antonella Sarasini, Maria Grazia Revello, Nadia L. Bernasconi, Erica Dander, Fabrizia Vanzetta, Annalisa Macagno, Federica Sallusto, Antonio Lanzavecchia, Macagno, A, Bernasconi, N, Vanzetta, F, Dander, E, Sarasini, A, Revello, M, Gerna, G, Sallusto, F, and Lanzavecchia, A
- Subjects
Human cytomegalovirus ,Cytomegalovirus Infection ,Cytomegalovirus ,Antibodies, Viral ,Epitope ,Epitopes ,Mice ,0302 clinical medicine ,Viral Envelope Proteins ,Pregnancy ,Pregnancy Complications, Infectious ,Neutralizing antibody ,0303 health sciences ,Membrane Glycoproteins ,biology ,Antibodies, Monoclonal ,Viral Envelope Protein ,3. Good health ,Cytomegalovirus Infections ,Female ,Membrane Glycoprotein ,Antibody ,Neutralization Test ,medicine.drug ,Human ,medicine.drug_class ,Immunology ,Molecular Sequence Data ,Congenital cytomegalovirus infection ,Monoclonal antibody ,Microbiology ,Cell Line ,03 medical and health sciences ,Antigen ,Neutralization Tests ,Virology ,medicine ,Animals ,Humans ,Amino Acid Sequence ,030304 developmental biology ,Animal ,Cytomegaloviru ,medicine.disease ,Antibodies, Neutralizing ,Insect Science ,biology.protein ,Pregnancy Complications, Infectiou ,Pathogenesis and Immunity ,Cytomegalovirus vaccine ,030215 immunology - Abstract
Human cytomegalovirus (HCMV) is a widely circulating pathogen that causes severe disease in immunocompromised patients and infected fetuses. By immortalizing memory B cells from HCMV-immune donors, we isolated a panel of human monoclonal antibodies that neutralized at extremely low concentrations (90% inhibitory concentration [IC 90 ] values ranging from 5 to 200 pM) HCMV infection of endothelial, epithelial, and myeloid cells. With the single exception of an antibody that bound to a conserved epitope in the UL128 gene product, all other antibodies bound to conformational epitopes that required expression of two or more proteins of the gH/gL/UL128-131A complex. Antibodies against gB, gH, or gM/gN were also isolated and, albeit less potent, were able to neutralize infection of both endothelial-epithelial cells and fibroblasts. This study describes unusually potent neutralizing antibodies against HCMV that might be used for passive immunotherapy and identifies, through the use of such antibodies, novel antigenic targets in HCMV for the design of immunogens capable of eliciting previously unknown neutralizing antibody responses.
- Published
- 2009
19. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-ζ activating signal
- Author
-
Virna Marin, Chihaya Imai, Andrea Biondi, Giovanna D'Amico, Harumi Kakuda, Dario Campana, Erica Dander, Marin, V, Kakuda, H, Dander, E, Imai, C, Campana, D, Biondi, A, and D'Amico, G
- Subjects
Cancer Research ,Recombinant Fusion Proteins ,Receptor expression ,medicine.medical_treatment ,Antigens, CD19 ,Bone Marrow Cells ,chemical and pharmacologic phenomena ,Biology ,Lymphocyte Activation ,Antigen ,Transduction, Genetic ,hemic and lymphatic diseases ,Genetics ,medicine ,Humans ,Cytotoxic T cell ,Child ,Molecular Biology ,Cells, Cultured ,B-Lymphocytes ,Leukemia, cytokine, killer cells, chimeric receptor ,Cytokine-induced killer cell ,Antibodies, Monoclonal ,CD28 ,hemic and immune systems ,Cell Biology ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Cytotoxicity Tests, Immunologic ,Molecular biology ,Coculture Techniques ,Killer Cells, Natural ,Cytokine ,Cancer research ,Interleukin 12 ,Cytokines ,Tumor necrosis factor alpha ,Signal Transduction - Abstract
Objective: There is growing interest in the use of cytokine-induced killer (CIK) cells in cancer therapy. In this study, we sought to maximize the antileukemic activity of anti-CD19 receptor-modified CIK cells against B-lineage acute lymphoblastic leukemia (ALL). Materials and Methods: CIK cells were transduced with retroviral vectors carrying different types of anti-CD19 chimeric receptors: anti-CD19-ζ, anti-CD19-DAP10, anti-CD19-4-1BB-ζ, and anti-CD19-CD28-ζ. A truncated form of the receptor was used as a control. Transduced CIK cells were then analyzed for their cytotoxic activity against ALL cells and for their capability to proliferate and to release cytokines after ALL encounter. Results: CIK cells were efficiently transduced with all the anti-CD19 retroviral vectors. Anti-CD19 receptor expression conferred powerful killing activity against ALL cells. However, there were clear advantages when receptors containing the co-stimulatory molecules 4-1BB or CD28 were transduced. Such cells had significantly more potent cytotoxicity than cells expressing the anti-CD19-ζ or anti-CD19-DAP10. Moreover, the presence of 4-1BB or CD28 in the receptor increased the production of interleukin (IL)-2, tumor necrosis factor (TNF)-α, TNF-β, IL-5, IL-6, and IL-8 elicited by coculture with ALL cells. Notably, anti-CD19-4-1BB-ζ CIK cells secreted particularly low levels of interleukin-10 and proliferated strongly after contact with ALL cells. Conclusions: Anti-CD19 chimeric receptors delivering primary and costimulatory signals render CIK cells powerfully cytotoxic against ALL cells and induce secretion of immunostimulatory cytokines and proliferation. These results support the testing of genetically modified CIK cells in clinical trials. © 2007 ISEH - Society for Hematology and Stem Cells.
- Published
- 2007
20. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study
- Author
-
Ettore Biagi, Anna Grassi, Enrico Pogliani, Giovanna D'Amico, Tiziano Barbui, Alessandro Rambaldi, Martino Introna, Erica Dander, Raewyn Broady, Marta Franceschetti, Josée Golay, Elena Conti, Orietta Spinelli, Gianmaria Borleri, Donatella Baronciani, Andrea Biondi, Matteo Parma, Giuseppe Gaipa, Anna Maria Barbui, Introna, M, Borleri, G, Conti, E, Franceschetti, M, Barbui, A, Broady, R, Dander, E, Gaipa, G, D'Amico, G, Biagi, E, Parma, M, Pogliani, E, Spinelli, O, Baronciani, D, Grassi, A, Golay, J, Barbui, T, Biondi, A, and Rambaldi, A
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Chronic myelomonocytic leukemia ,Hematopoietic stem cell transplantation ,Gastroenterology ,CIK, BMT, cell therapy ,Recurrence ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Salvage Therapy ,Chemotherapy ,Cytokine-induced killer cell ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,medicine.disease ,Donor Lymphocytes ,Killer Cells, Natural ,Transplantation ,Haematopoiesis ,Leukemia ,Hematologic Neoplasms ,Lymphocyte Transfusion ,Immunology ,Cytokines ,Female ,business - Abstract
BACKGROUND AND OBJECTIVES: Cytokine-induced killer (CIK) cells have shown anti-leukemic activity and little graft-versus-host disease (GVHD) in several animal models. The safety of these cells in autologous settings has been shown. We performed a phase I study of allogeneic (donor's) CIK cells in patients relapsing after allogeneic haematopoietic stem cell transplantation (HSCT). DESIGN AND METHODS: Eleven patients with acute myelogenous leukemia (n=4), Hodgkin's disease (n=3), chronic myelomonocytic leukemia, (n=1), pre-B acute lymphoblastic leukemia (n=1) and myelodysplasia (n=2), all of whom had relapsed after sibling (n=6) or matched unrelated donor (n=5) HSCT, entered this study. RESULTS: Before CIK administration, six patients had received other salvage treatments including chemotherapy (n=5), radiotherapy (n=1) and unmanipulated donor lymphocytes (n=6) without any significant tumor response. The median number of CIK infusions was two (range 1-7) and the median number of total CIK cells was 12.4x106/kg (range 7.2-87.4). The infusions were well tolerated and no acute or late infusion-related reactions were recorded. Acute GVHD (grade I and II) was observed in four patients, 30 days after the last CIK infusion, and progressed into extensive chronic GVHD in two cases. Disease progression and death occurred in six patients. One patient had stable disease, one had hematologic improvement and three achieved complete responses. INTERPRETATION AND CONCLUSIONS: This study shows that the production of allogeneic CIK cells is feasible under clinical-grade conditions, well tolerated and may contribute to clinical responses.
- Published
- 2007
21. T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy
- Author
-
Virna Marin, Martín Hernán Bonamino, Giuseppe Basso, Adriana Balduzzi, Erica Dander, Andrea Biondi, Giovanna D'Amico, Ettore Biagi, D'Amico, G, Bonamino, M, Dander, E, Marin, V, Basso, G, Balduzzi, A, Biagi, E, and Biondi, A
- Subjects
Cancer Research ,T cell ,CD40 Ligand ,Antigen-Presenting Cells ,Bone Marrow Cells ,Cell Communication ,Immunophenotyping ,Interleukin 21 ,Cell Movement ,Humans ,Medicine ,Cytotoxic T cell ,Cell Lineage ,IL-2 receptor ,Child ,Antigen-presenting cell ,Cells, Cultured ,CD40L, leukemia, adoptive immunotherapy ,Interleukin 3 ,B-Lymphocytes ,business.industry ,Dendritic Cells ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Th1 Cells ,Natural killer T cell ,Adoptive Transfer ,Coculture Techniques ,medicine.anatomical_structure ,Oncology ,Immunology ,Cancer research ,Interleukin 12 ,business ,Immunologic Memory - Abstract
Adoptive T-cell immunotherapy may provide complementary therapy for childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In this study, we have analyzed the functional characteristics of anti-BCP-ALL effector T cells generated by co-culturing T lymphocytes and dendritic cells (DC) from allogeneic human stem cell transplantation (HSCT) donors. After 21-day co-culture with DC pulsed with CD40L+ apoptotic BCP-ALL blasts, T cells presented with both effector and central memory phenotype, and showed high and specific cytotoxic activity against leukemic cells (average lysis = 77%), mostly mediated by CD8+ T cells. Noticeably, growth of CD4 T cells was maintained (45% of total cells), which actively produced Th1 cytokines (IFN-gamma, TNF-alpha, IL-2), but not IL-4, IL-5 and IL-10. Anti-BCP-ALL T cells expressed CD49d and CXCR4 (implicated in the recruitment to bone marrow), and CD62L and CCR7 (involved in the migration to lymphoid organs). In accordance with this profile, T cells significantly migrated in response to the chemokines CXCL12 and CCL19. In conclusion, stimulation of T cells with CD40L+BCP-ALL cells-loaded DC not only elicited the generation of potent and specific anti-leukemic cytotoxic effectors, but also the differentiation of specific and functional Th-1 CD4 lymphocytes. These effectors are fully equipped to reach leukemia-infiltrated tissues and have characteristics to support and orchestrate the anti-tumor immune-response.
- Published
- 2006
22. Defective dendritic cell migration and activation of adaptive immunity in PI3Kγ-deficient mice
- Author
-
Amerigo Santoro, Annunciata Vecchi, Fabio Facchetti, Alberto Mantovani, Karel Otero, Marina Sironi, Erica Dander, Walter Luini, Laura Barberis, Emilio Hirsch, Matthias P. Wymann, Silvano Sozzani, Cecilia Garlanda, Sergio Bernasconi, William Vermi, Annalisa Del Prete, Del Prete, A, Vermi, W, Dander, E, Otero, K, Barberis, L, Luini, W, Bernasconi, S, Sironi, M, Santoro, A, Garlanda, C, Facchetti, F, Wymann, M, Vecchi, A, Hirsch, E, Mantovani, A, and Sozzani, S
- Subjects
Male ,Chemokine ,T-Lymphocytes ,In Vitro Techniques ,Dermatitis, Contact ,Article ,General Biochemistry, Genetics and Molecular Biology ,Mice ,Phosphatidylinositol 3-Kinases ,Dendritiic cell ,Immune system ,Cell Movement ,medicine ,Animals ,Class Ib Phosphatidylinositol 3-Kinase ,1-Phosphatidylinositol 3-Kinase ,Hypersensitivity, Delayed ,chemotaxis ,Dendritic cell migration ,Molecular Biology ,Lymph node ,contact hypersensitivity ,Mice, Knockout ,General Immunology and Microbiology ,biology ,Animal ,General Neuroscience ,Dendritic Cells ,Dendritic cell ,Chemokines, cell migration, Knockout mice ,Acquired immune system ,chemokines ,dendritic cells ,PI3Kγ−/− mice ,Dendric cells ,Cell biology ,Isoenzymes ,medicine.anatomical_structure ,Langerhans Cells ,Immunology ,biology.protein ,Lymph ,Chemokines ,Ex vivo - Abstract
Gene-targeted mice were used to evaluate the role of the gamma isoform of phosphoinositide 3-kinase (PI3Kgamma) in dendritic cell (DC) migration and induction of specific T-cell-mediated immune responses. DC obtained from PI3Kgamma-/- mice showed a reduced ability to respond to chemokines in vitro and ex vivo and to travel to draining lymph nodes under inflammatory conditions. PI3Kgamma-/- mice had a selective defect in the number of skin Langerhans cells and in lymph node CD8alpha- DC. Furthermore, PI3Kgamma-/- mice showed a defective capacity to mount contact hypersensitivity and delayed-type hypersensitivity reactions. This defect was directly related to the reduced ability of antigen-loaded DC to migrate from the periphery to draining lymph nodes. Thus, PI3Kgamma plays a nonredundant role in DC trafficking and in the activation of specific immunity. Therefore, PI3Kgamma may be considered a new target to control exaggerated immune reactions.
- Published
- 2004
23. Immunosuppression does not affect human bone marrow mesenchymal stromal cell efficacy after transplantation in traumatized mice brain
- Author
-
Ettore Biagi, Maria Grazia De Simoni, Elisa R. Zanier, Francesca Pischiutta, Giovanna D'Amico, Giuseppe Citerio, Andrea Biondi, Erica Dander, Pischiutta, F, D'Amico, G, Dander, E, Biondi, A, Biagi, E, Citerio, G, De Simoni, M, and Zanier, E
- Subjects
Graft Rejection ,Male ,Pathology ,medicine.medical_specialty ,Stromal cell ,Traumatic brain injury ,medicine.medical_treatment ,Gene Expression ,Neuropsychological Tests ,Mesenchymal Stem Cell Transplantation ,Cellular and Molecular Neuroscience ,Mice ,Traumatic brain injury, Stem cell transplantation, Mesenchymal stromal cells, Cyclosporin A, Immunosuppression, Brain protection ,Cyclosporin a ,medicine ,Animals ,Humans ,Pharmacology ,Immunosuppression Therapy ,business.industry ,Mesenchymal stem cell ,Sham surgery ,Brain ,Immunosuppression ,Mesenchymal Stem Cells ,Recovery of Function ,medicine.disease ,Transplantation ,Mice, Inbred C57BL ,medicine.anatomical_structure ,Treatment Outcome ,Brain Injuries ,Immunology ,Cyclosporine ,Bone marrow ,business ,Immunosuppressive Agents - Abstract
The need for immunosuppression after allo/xenogenic mesenchymal stromal cell (MSC) transplantation is debated. This study compared the long-term effects of human (h) bone marrow MSC transplant in immunocompetent or immunosuppressed traumatic brain injured (TBI) mice. C57Bl/6 male mice were subjected to TBI or sham surgery followed 24 h later by an intracerebroventricular infusion of phosphate buffer saline (PBS, control) or hMSC (150,000/5 μl). Immunocompetent and cyclosporin A immunosuppressed (CsA) mice were analyzed for gene expression at 72 h, functional deficits and histological analysis at five weeks. Gene expression analysis showed the effectiveness of immunosuppression (INFγ reduction in CsA treated groups), with no evidence of early rejection (no changes of MHCII and CD86 in all TBI groups) and selective induction of T-reg (increase of Foxp3) only in the TBI hMSC group. Five weeks after TBI, hMSC had comparable efficacy, with functional recovery (on both sensorimotor and cognitive deficits) and structural protection (contusion volume, vessel rescue effect, gliotic scar reduction, induction of neurogenesis) in immunosuppressed and immunocompetent mice. Therefore, long-term hMSC efficacy in TBI is not dependent on immunosuppressive treatment. These findings could have important clinical implication since immunosuppression in acute TBI patients may increase their risk of infection and not be tolerated. © 2013 Elsevier Ltd. All rights reserved.
- Published
- 2013
24. ENCAPSULATED MESENCHYMAL STEM CELLS FOR IN VIVO IMMUNOMODULATION
- Author
-
Marina G. M. Castor, Giovanna D'Amico, Anna Elisa Trovato, Francesco Mancuso, Mario Calvitti, Riccardo Calafiore, Iva Arato, Antonella Viola, Erica Dander, Giovanni Luca, Andrea Biondi, Cristiana Soldani, Javier Cibella, C. Ploia, Nives Jonjić, M. Golemac, L. Zanotti, Adelaida Sarukhan, Massimo Locati, Zanotti, L, Sarukhan, A, Dander, E, Castor, M, Cibella, J, Soldani, C, Trovato, A, Ploia, C, Luca, G, Calvitti, M, Mancuso, F, Arato, I, Golemac, M, Jonjic, N, Biondi, A, Calafiore, R, Locati, M, D'Amico, G, and Viola, A
- Subjects
Cancer Research ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences ,Alginates ,Ovalbumin ,medicine.medical_treatment ,Transgene ,T-Lymphocytes ,In vivo immunomodulation ,Clinical uses of mesenchymal stem cells ,Graft vs Host Disease ,Mice, Transgenic ,mesenchymal stem cells, in vivo, immunomodulation ,Biology ,Inbred C57BL ,Mesenchymal Stem Cell Transplantation ,Transgenic ,Immunomodulation ,stem cells ,in vivo immunomodulation ,Mice ,Cancer immunotherapy ,Glucuronic Acid ,In vivo ,medicine ,Adipocytes ,Animals ,Inbred BALB C ,Stem cell transplantation for articular cartilage repair ,Mice, Inbred BALB C ,Osteoblasts ,Mesenchymal Stromal Cells ,Hexuronic Acids ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti ,Mesenchymal stem cell ,BIOMEDICINE AND HEALTHCARE. Basic Medical Sciences ,Mice, Inbred C57BL ,Survival Rate ,Hematology ,Anesthesiology and Pain Medicine ,MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Cell biology ,Endothelial stem cell ,Oncology ,Immunology ,Mesenchymal stem cells ,BIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti ,Tumor immunology - Abstract
Mesenchymal stem cells (MSCs) are self-renewable, multipotent progenitor cells able to differentiate into various mesodermal lineages.1 MSCs are present in basically all tissues, and have a pivotal role in tissue repair and in local control of inflammation.
- Published
- 2013
25. Role Of Long Pentraxin 3 (PTX3) In Wound Closure Induced By Bone Marrow-Derived Mesenchymal Stromal Cells
- Author
-
Alberto Mantovani, Andrea Biondi, Barbara Bottazzi, Cecilia Garlanda, Giovanna D'Amico, Andrea Doni, Fabio Pasqualini, Claudia Cappuzzello, Erica Dander, Manuela Nebuloni, Cappuzzello, C, Doni, A, Dander, E, Pasqualini, F, Nebulosi, M, Bottazzi, B, Mantovani, A, Biondi, A, Garlanda, C, and D'Amico, G
- Subjects
Mesenchymal Stromal Cells ,medicine.medical_treatment ,Growth factor ,Immunology ,Mesenchymal stem cell ,Granulation tissue ,Cell Biology ,Hematology ,Biology ,Biochemistry ,Proinflammatory cytokine ,Extracellular matrix ,Cytokine ,medicine.anatomical_structure ,medicine ,Cancer research ,Bone marrow ,Wound healing ,PTX3 - Abstract
Although several studies have shown the capacity of mesenchymal stromal cells (MSCs) to repair and regenerate different tissues, the mechanisms underlying these processes are not understood. Long Pentraxin 3 (PTX3) is a multifunctional protein produced by MSCs and other cell subsets upon activation with inflammatory cytokines. PTX3 is involved in innate immunity, inflammation and extracellular matrix deposition. In the present study we analyzed the potential role of PTX3 in wound repair process induced by MSCs. PTX3 knockout MSCs (PTX3-/-MSCs) were collected from bone marrow of PTX3-/- mice. After 3-5 culture passages the expression of surface markers was analyzed by flow cytometry and their osteogenic and adipogenic differentiation capacity was detected by alizarin red O and oil red S staining, respectively. The ability of PTX3-/-MSCs to abrogate T cell proliferation was evaluated by co-culturing MSCs and PBMCs previously activated with Phytohaemagglutinin. Finally, equal number of both PTX3-/-MSCs and wild type (WT) MSCs were implanted into excisional wounds created by a biopsy punch on the back of allogenic WT and PTX3-/- mice. Wound area was measured up to 14 day and calculated using an image analysis program. The wound specimens were collected at 2, 7 and 14 days and processed for histological analysis. We demonstrated that PTX3-/-MSCs, similarly to WT MSCs, displayed typical fibroblastoid morphology, they expressed common MSC markers and were able to differentiate into adipocytes and osteoblasts. In addition, they drastically decreased the mitogen-induced proliferation of lymphocyte. Importantly, in a mouse model of wound healing, PTX3-/- MSCs showed a highly significant defect in wound closure compared to WT MSCs at each time point. Histological evaluation of skin samples treated with PTX3-/- MSCs showed a reduction of the granulation tissue and a significant increase of neutrophils (GR-1+) in the wound bed. Moreover, wounds treated with PTX3-/- MSCs were characterized by an excessive accumulation of fibrin at the 2nd day after injury. Accordingly, PTX3-/- MSCs showed a defective ability to degrade the fibrin matrix in vitro. Finally, PTX3-/- MSCs failed to close the ulcers in PTX3-/- mice. In conclusion, we demonstrated that PTX3 deficiency does not alter the phenotype and the capacity of MSCs to differentiate into mesengetic lineages; however, the production of PTX3 represents an essential requirement for MSC ability of enhancing tissue repair. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2013
26. Pentraxin-3 Increases At The Onset Of Graft-Versus-Host Disease In Transplanted Patients
- Author
-
DANDER, ERICA, VINCI, PAOLA, PAVAN, FABIO, VALSECCHI, MARIA GRAZIA, BIONDI, ANDREA, Lorenzo, P, Cuccovillo, I, Bonanomi, S, Balduzzi, A, Migliavacca, M, Maio, L, Teruzzi, E, Garlanda, C, Mantovani, A, Rovelli, A, Bottazzi, B, D’Amico, G., Dander, E, Vinci, P, Lorenzo, P, Cuccovillo, I, Bonanomi, S, Balduzzi, A, Migliavacca, M, Maio, L, Pavan, F, Teruzzi, E, Garlanda, C, Mantovani, A, Valsecchi, M, Rovelli, A, Bottazzi, B, Biondi, A, and D’Amico, G
- Subjects
GVHD ,Transplanted ,PTX3 - Published
- 2012
27. LONG TERM SURVIVAL AND EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT DEPENDENT ON IMMUNOSUPPRESSIVE TREATMENT
- Author
-
Pischiutta, F, Zanier, ER, D'Amico, G, DANDER, ERICA, BIAGI, ETTORE, De Simoni, M.G., GAIPA, GIUSEPPE, BIONDI, ANDREA, CITERIO, GIUSEPPE, Pischiutta, F, Zanier, E, D'Amico, G, Dander, E, Gaipa, G, Biondi, A, Biagi, E, Citerio, G, and De Simoni, M
- Subjects
HUMAN BONE MARROW MESENCHYMAL STEM CELLS ,IMMUNOSUPPRESSIVE TREATMENT ,LONG TERM SURVIVAL ,MICE BRAIN - Published
- 2012
28. Mesenchymal stem cells from Shwachman-Diamond syndrome patients display normal functions and do not contribute to hematological defects
- Author
-
Marta Galbiati, Alan J. Warren, C Cappuzzello, Erica Dander, Giovanna D'Amico, G te Kronnie, A Di Meglio, Valentina Andre, Emanuela Maserati, Marco Cipolli, Andrea Biondi, Cristina Bugarin, Laura Sainati, Giovanni Cazzaniga, Daniela Longoni, M Serafini, Elena Nicolis, Silvia Bresolin, André, V, Longoni, D, Bresolin, S, Cappuzzello, C, Dander, E, Galbiati, M, Bugarin, C, Di Meglio, A, Nicolis, E, Maserati, E, Serafini, M, Warren, A, Te Kronnie, G, Cazzaniga, G, Sainati, L, Cipolli, M, Biondi, A, D'Amico, G, Warren, Alan [0000-0001-9277-4553], and Apollo - University of Cambridge Repository
- Subjects
Hematopoietic stem cell niche ,CD34 ,Keywords: Shwachman–Diamond syndrome ,Mesenchymal stem cells, Shwachman-Diamond syndrome, hematological defects ,medicine ,SBDS ,Keywords: Shwachman–Diamond syndrome, mesenchymal stem cells, bone marrow failure, SBDS ,Shwachman–Diamond syndrome ,mesenchymal stem cells ,business.industry ,Shwachman-Diamond syndrome ,Mesenchymal stem cell ,Hematology ,medicine.disease ,Leukemia ,Haematopoiesis ,medicine.anatomical_structure ,Oncology ,bone marrow failure ,Immunology ,Cancer research ,Original Article ,Bone marrow ,Stem cell ,business - Abstract
Shwachman-Diamond syndrome (SDS) is a rare inherited disorder characterized by bone marrow (BM) dysfunction and exocrine pancreatic insufficiency. SDS patients have an increased risk for myelodisplastic syndrome and acute myeloid leukemia. Mesenchymal stem cells (MSCs) are the key component of the hematopoietic microenvironment and are relevant in inducing genetic mutations leading to leukemia. However, their role in SDS is still unexplored. We demonstrated that morphology, growth kinetics and expression of surface markers of MSCs from SDS patients (SDS-MSCs) were similar to normal MSCs. Moreover, SDS-MSCs were able to differentiate into mesengenic lineages and to inhibit the proliferation of mitogen-activated lymphocytes. We demonstrated in an in vitro coculture system that SDS-MSCs, significantly inhibited neutrophil apoptosis probably through interleukin-6 production. In a long-term coculture with CD34+-sorted cells, SDS-MSCs were able to sustain CD34+ cells survival and to preserve their stemness. Finally, SDS-MSCs had normal karyotype and did not show any chromosomal abnormality observed in the hematological components of the BM of SDS patients. Despite their pivotal role in the hematopoietic stem cell niche, our data suggest that MSC themselves do not seem to be responsible for the hematological defects typical of SDS patients. © 2012 Macmillan Publishers Limited All rights reserved.
- Published
- 2012
29. Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation
- Author
-
Giovanna D'Amico, Ettore Biagi, Giuseppe Gaipa, Irene Di Ceglie, Paolo Perseghin, Erica Dander, Alessandra Algarotti, Martino Introna, Alessandro Rambaldi, Giovanna Lucchini, Andrea Biondi, Adriana Balduzzi, Fabio Pavan, Attilio Rovelli, Lucchini, G, Dander, E, Pavan, F, Di Ceglie, I, Balduzzi, A, Perseghin, P, Gaipa, G, Algarotti, A, Introna, M, Rambaldi, A, Rovelli, A, Biondi, A, Biagi, E, and D'Amico, G
- Subjects
lcsh:Internal medicine ,Article Subject ,business.industry ,Lymphocyte ,medicine.medical_treatment ,Mesenchymal stem cell ,Immunosuppression ,Cell Biology ,Mesenchymal stromal cells, MSC, BMT, viral infections ,medicine.disease ,Virus ,Transplantation ,medicine.anatomical_structure ,Graft-versus-host disease ,Immunology ,Clinical Study ,Medicine ,Stem cell ,business ,lcsh:RC31-1245 ,Molecular Biology ,Whole blood - Abstract
Mesenchymal stromal cells (MSC) are tested in clinical trials to treat graft versus host disease (GvHD) after stem cell transplantation (SCT).In vitrostudies demonstrated MSC's broad immunosuppressive activity. As infections represent a major risk after SCT, it is important to understand the role of MSC in this context. We analyzed 24 patients (pts) receiving MSC for GvHD in our Unit between 2009 and 2011. We recorded viral reactivations as measured in whole blood with polymerase chain reaction for 100 days following MSC administration. In patients with a documented viral reactivation in the first 3 days following MSCs infusion the frequency of virus-specific IFNgamma-producing cells was determined through enzyme-linked immunospot assay. In our cohort of patients viral reactivation after MSC infusion occurred in 45% of the cases, which did not significantly differ from the incidence in a historical cohort of patients affected by steroid resistant GvHD and treated with conventional immunosuppression. No patient presented severe form of infection. Two cases could be checked for immunological response to viral stimulus and demonstrated virus specific T-cytotoxic lymphocyte activity. In our experience MSC infusion did not prove to trigger more frequent or severer viral reactivations in the post transplantation setting.
- Published
- 2012
30. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation
- Author
-
Paolo Perseghin, Greta Zappa, Ettore Biagi, Matteo Parma, Giovanna D'Amico, Adriana Balduzzi, Elisabetta Todisco, Pamela Della Mina, Attilio Rovelli, Maddalena Migliavacca, Emilio Berti, Daoud Rahal, Andrea Biondi, Daniela Longoni, Paola Allavena, Valentina Andre, Antonello Villa, Giovanna Lucchini, Erica Dander, Graziella Solinas, Dander, E, Balduzzi, A, Zappa, G, Lucchini, G, Perseghin, P, André, V, Todisco, E, Rahal, D, Migliavacca, M, Longoni, D, Solinas, G, Villa, A, Berti, E, Mina, P, Parma, M, Allavena, P, Biagi, E, Rovelli, A, Biondi, A, and D'Amico, G
- Subjects
Adult ,Male ,GvHD, Th-17, immunotherapy ,Time Factors ,Adolescent ,medicine.medical_treatment ,Graft vs Host Disease ,Enzyme-Linked Immunosorbent Assay ,T-Lymphocytes, Regulatory ,Interferon-gamma ,Young Adult ,immune system diseases ,medicine ,Humans ,Transplantation, Homologous ,Lymphocyte Count ,Child ,Aged ,Skin ,Transplantation ,Microscopy, Confocal ,business.industry ,ELISPOT ,Interleukin-17 ,Hematopoietic Stem Cell Transplantation ,Interleukin ,Infant ,Forkhead Transcription Factors ,Receptors, Interleukin ,T-Lymphocytes, Helper-Inducer ,Middle Aged ,medicine.disease ,Flow Cytometry ,Haematopoiesis ,surgical procedures, operative ,Graft-versus-host disease ,Cytokine ,Liver ,Case-Control Studies ,Child, Preschool ,Immunology ,Female ,Interleukin 17 ,Stem cell ,Inflammation Mediators ,business ,Biomarkers - Abstract
Objectives. Graft-versus-host disease (GVHD) is a major obstacle to safe allogeneic hematopoietic stem-cell transplantation, leading to significant mortality. Recently, T-helper (TH)-17 cells have been shown to play a central role in mediating several autoimmune diseases. The aim of our study was to investigate the relationship between TH-17 cells and GVHD occurring in transplanted patients. Methods. Blood samples were collected from 51 hematopoietic stem-cell transplantation patients and 15 healthy donors. Patients with GVHD were monitored for the presence of TH-17 cells by ELISPOT or flow cytometry in the peripheral blood and by confocal microscopy in GVHD lesions. Cytokine plasma levels were detected by ELISA. Results. An increased TH-17 population (up to 4.8% of peripheral blood CD4+T lymphocytes) was observed in patients with acute GVHD and (up to 2.4%) in patients with active chronic GVHD along with an inflammatory process. In contrast, the percentage of TH-17 cells drastically decreased in patients with inactive chronic GVHD. TH-17 cells consisted of both interleukin (IL)-17(+)/interferon (IFN)-gamma(-) and IL-17(+)/IFN-gamma(+) subsets and expressed IL-23 receptor. Interestingly, IFN-gamma(+)TH-17 cells were able to infiltrate GVHD lesions as observed in liver and skin sections. Moreover, the proportion of TH-17 was inversely correlated with the proportion of regulatory T cells observed in the peripheral blood and tissues affected by GVHD. Finally, we demonstrated a strong correlation between TH-17 levels and the clinical status of patients with GVHD. Conclusions. These findings support the hypothesis that TH-17 are involved in the active phases of GVHD and may represent a novel cellular target for developing new strategies for GVHD treatment.
- Published
- 2009
31. Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T-cell lines expanded by a selective peptide library
- Author
-
Giuliano Renoldi, Virna Marin, Martino Introna, Ettore Biagi, Fabrizio Manca, Andrea Biondi, Giuseppina Li Pira, Giuseppe Gaipa, Giovanna D'Amico, Paolo Perseghin, Erica Dander, Dander, E, Li Pira, G, Biagi, E, Perseghin, P, Renoldi, G, Gaipa, G, Introna, M, Marin, V, Manca, F, Biondi, A, and D'Amico, G
- Subjects
Cancer Research ,Cellular immunity ,medicine.medical_treatment ,T cell ,Cell Culture Techniques ,Cytomegalovirus ,Biology ,Immunologic Tests ,CXCR3 ,Viral Proteins ,Immune system ,Cell Movement ,Peptide Library ,Genetics ,medicine ,Cytotoxic T cell ,Humans ,IL-2 receptor ,Molecular Biology ,Cells, Cultured ,Cell Proliferation ,virus diseases ,Cell Biology ,Hematology ,Dendritic Cells ,T-Lymphocytes, Helper-Inducer ,Flow Cytometry ,Cytokine ,medicine.anatomical_structure ,CMV, GMP, cell therapy ,Immunology ,Cytokines ,CD8 ,T-Lymphocytes, Cytotoxic - Abstract
Objective Reconstitution of cellular immunity by infusion of cytomegalovirus (CMV)-specific T lymphocytes is an attractive alternative to drugs currently used to control CMV reactivation in immunocompromised patients. For this purpose, we established a method for generating both anti-CMV CD4 and CD8 T cells following Good Manufacturing Practice indications, and we extensively characterized their immune functions. Materials and Methods For generating CD4 and CD8 CMV-specific lymphocytes, T cells from 11 CMV-seropositive donors were stimulated three times with dendritic cells (DC) pulsed with a library of selected CMV peptides, recognized by >85% of the Caucasian population. At the end of the culture, T cells were analyzed for their specificity, cytotoxicity, chemotactic migration, proliferation, and cytokine production. Results T cells were successfully expanded and enriched in CMV-specific subsets with an effector memory or an effector memory CD45 RA + phenotype. CMV-specific T-cell lines showed specific cytotoxicity (average lysis: 47%) against CMV peptides-pulsed DCs, and were depleted of auto- and alloreactivity. Moreover, the ability to proliferate following antigenic stimulation and the presence of functional CD4 lymphocytes producing Th1 and Th2 cytokines can ensure long-term antiviral immunity after in vivo injection. CMV-specific T lymphocytes also proved to be fully equipped to reach CMV-infected tissues, because they expressed CD49d and CCR1, CXCR3, CXCR4, necessary to recruit effector cells to inflamed sites. In accordance with this profile, they significantly migrated towards inflammatory chemokines and towards the supernatant collected from inflamed lung fibroblasts, frequently involved in CMV pathology. Conclusion This strategy allows expansion of effector T cells capable to exert CD8 and CD4-mediated immune functions and, thus, is suitable for clinical use.
- Published
- 2007
32. Chimeric T-cell receptors: New challenges for targeted immunotherapy in hematologic malignancies
- Author
-
Ettore Biagi, Andrea Biondi, Erica Dander, Giovanna D'Amico, Greta Maria Paola Giordano Attianese, Virna Marin, Biagi, E, Marin, V, Giordano Attianese, G, Dander, E, D'Amico, G, and Biondi, A
- Subjects
Adult ,medicine.drug_class ,medicine.medical_treatment ,Recombinant Fusion Proteins ,CD33 ,Antigens, CD19 ,Sialic Acid Binding Ig-like Lectin 3 ,Receptors, Antigen, T-Cell ,Antigens, Differentiation, Myelomonocytic ,Ki-1 Antigen ,T-Cell Antigen Receptor Specificity ,Biology ,Monoclonal antibody ,CD19 ,Targeted therapy ,Drug Delivery Systems ,Antigen ,Antigens, CD ,Antigens, Neoplasm ,hemic and lymphatic diseases ,Neoplasms ,medicine ,Animals ,Humans ,Child ,CD20 ,Clinical Trials as Topic ,Hematology ,Immunotherapy ,medicine.disease ,Antigens, CD20 ,Killer Cells, Natural ,Leukemia ,Hematologic Neoplasms ,Immunology ,biology.protein ,Chimeric T-cell receptor, leukemia, cell therapy, gene therapy ,Forecasting ,T-Lymphocytes, Cytotoxic - Abstract
Chimeric T-cell receptors (ChTCR), are a fascinating technological step in the field of immunotherapy for orienting the activity of immune cells towards specific molecular targets expressed on the cell surface of various tumors, including hematologic malignancies. The main characteristics of ChTCR are their ability to redirect T-cell specificity and their killing/effector activity toward a selected target in a non MHC-restricted manner, exploiting the antigen binding properties of monoclonal antibodies. ChTCR are, in fact, artificial T-cell receptors constituted by an antigen-recognizing antibody molecule linked to a T-cell triggering domain. Various hematologic malignancies represent optimal targets for the exploitation of ChTCR, because of the bright expression of specific antigens on the surface of tumor cells. Thus, CD19 and CD20 have been targeted for B-cell lymphoid tumors (acute lymphoblastic leukemia-ALL, lymphomas and chronic lymphocytic leukemia-CLL), CD33 for myeloid leukemia, and CD30 for lymphomas. Even though technical and safety progresses are still needed to improve the profile of gene transfer and protein expression of ChTCR, phase 1 trials will be carried out in the near future to demonstrate the feasibility of their clinical translation and, it is be hoped, give preliminary indications about their anti-tumor efficacy.
- Published
- 2007
33. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy
- Author
-
Giovanna D'Amico, Virna Marin, Erica Dander, Andrea Biondi, Ettore Biagi, Grazia Fazio, Martino Introna, Marin, V, Dander, E, Biagi, E, Introna, M, Fazio, G, Biondi, A, and D'Amico, G
- Subjects
Cytotoxicity, Immunologic ,Male ,Cancer Research ,CD3 ,Recombinant Fusion Proteins ,T-Lymphocytes ,Antigens, CD19 ,C-C chemokine receptor type 6 ,Biology ,Immunotherapy, Adoptive ,CD19 ,Antigen ,Antigens, CD ,Cell Movement ,Leukemic Infiltration ,Genetics ,Cytotoxic T cell ,Humans ,Child ,Killer Cells, Lymphokine-Activated ,Molecular Biology ,Matrigel ,Chimeric T-cell receptor, CIK, CD19, leukemia ,Cell Biology ,Hematology ,Natural killer T cell ,Molecular biology ,Burkitt Lymphoma ,Cell biology ,Child, Preschool ,biology.protein ,Female ,Receptors, Chemokine ,K562 Cells ,K562 cells - Abstract
Objective Cytokine-induced killer (CIK) cells are ex vivo expanded cells enriched in CD3 + CD56 + natural killer T (NKT) cells with major histocompatibility-unrestricted cytotoxicity against several tumoral targets, except B-lineage acute lymphoblastic leukemia (B-ALL). We redirected CIK cells cytotoxicity toward B-ALL with a chimeric receptor specific for the CD19 antigen and then explored if modified-CIK cells maintain the same chemotactic properties of freshly isolated NKT cells, whose trafficking machinery reflects their preferential localization into the sites of B-ALL infiltration. Material and Methods CIK cells were expanded ex vivo for 21 days and analyzed for expression of adhesion molecules and chemokine receptors regulating adhesion and homing toward leukemia-infiltrated tissues. CIK cells were then transduced with the anti-CD19-ζ-internal ribosomal entry site-green fluorescent protein retroviral vector and characterized for their cytotoxicity against B-ALL cells in a 51 Cr-release assay and for their trafficking properties, including chemotactic activity, adhesion and transendothelial migration, and metalloproteases-dependent invasion of Matrigel. Results Similarly to freshly isolated NKT cells, CD49d and CD11a were highly expressed on CIK cells. Moreover, CIK cells expressed CXCR4, CCR6, and CCR7 (mean expression 72%, 60%, and 32%, respectively), presenting chemotactic activity toward their respective ligands. Anti-CD19 chimeric receptor-modified CIK cells became cytotoxic against B-ALL cells (mean lysis, 60%) and showed, after exposure to a CXCL12 gradient, high capacity to adhere and transmigrate through endothelial cells and to invade Matrigel. Conclusion The potential capacity to localize into leukemia-infiltrated tissues of anti-CD19 chimeric receptor-redirected CIK cells, together with their ability to efficiently kill B-ALL cells, suggests that modified-CIK cells represent a valuable tool for leukemia immunotherapy.
- Published
- 2006
34. Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients
- Author
-
Attilio Rovelli, Daniela Longoni, Sara Deola, Josée Golay, Chiara Capelli, Paolo Perseghin, Giovanna Lucchini, Alessandra Algarotti, Irene Cavattoni, Anna Grassi, Erica Dander, Martino Introna, Adriana Balduzzi, Enrico Maria Pogliani, Fabio Pavan, Francesca Masciochi, Elisa Gotti, Sergio Cortelazzo, Giuseppe Gaipa, Matteo Parma, Andrea Biondi, Giovanna D'Amico, Ettore Biagi, Caterina Micò, Daniela Belotti, Alessandro Rambaldi, Introna, M, Lucchini, G, Dander, E, Rovelli, A, Balduzzi, A, Longoni, D, Pavan, F, Masciochi, F, Algarotti, A, Micò, C, Grassi, A, Cavattoni, I, Deola, S, Gaipa, G, Belotti, D, Perseghin, P, Parma, M, Pogliani, E, Golay, J, Gotti, E, Capelli, C, Cortelazzo, S, D'Amico, G, Biondi, A, Rambaldi, A, and Biagi, E
- Subjects
medicine.medical_specialty ,Hematology ,Mesenchymal Stromal Cells ,Graft Versus Host Disease ,Surrogate endpoint ,business.industry ,medicine.medical_treatment ,Immunology ,Immunosuppression ,Cell Biology ,Hematopoietic stem cell transplantation ,medicine.disease ,Biochemistry ,Gastroenterology ,Surgery ,Transplantation ,Graft-versus-host disease ,Median follow-up ,Internal medicine ,medicine ,Pentostatin ,business ,medicine.drug - Abstract
Abstract 743 Background: Acute Graft versus host disease (aGvHD) is a severe complication of allogeneic hematopoietic stem cell transplantation (HSCT). Conventional treatment with high dose steroids fails to achieve a complete and sustained response in more than 50% of patients. Several second line treatments have been described but none of these can be considered superior or a standard of care (Paul J. Martin et al, BBMT 2012). Among these treatments, the use of third party mesenchymal stromal cells (MSC) has been proposed (LeBlanc et al, Lancet 2008). In this study, we assessed the safety and efficacy of third party human MSC, in a prospective, multicenter, phase I study (EudraCT 2008–007869-23). Methods: Forty-seven patients with steroid-resistant, acute or chronic grade II-IV GvHD were enrolled into this study. Human MSC were obtained from bone marrow harvests of healthy donors and expanded in vitro using serum free medium supplemented with human platelet lysate (Capelli C et al, BMT, 2007; Capelli C. et al, Cytotherapy 2009). In vitro expanded MSC were produced in two officially authorized Cell Factories and tested in four Italian Hematology Units. The primary endpoint of this study was the safety. Secondary endpoints were the response of GvHD (evaluated 28 days after the last MSC infusion), as well as the overall survival and transplant-related deaths. Blood samples were periodically collected before and after MSC infusion to measure plasma levels of IL2Ralpha by ELISA, as previously described by our group (Dander E et al, Leukemia 2012). Results: Between August 2009, and June 2012, 47 patients (16 children, 31 adults, median age 25.5 years, range 1 to 67) were treated. The median dose of infused MSC was 1.5×106 cells per kg bodyweight. Enrolled patients presented with aGvHD in 37 cases, chronic overlap syndrome in 7 cases, and chronic classic GvHD in 3 cases. Fifteen pts had grade II GvHD, 23 grade III and 9 grade IV, according to NIH criteria. In 17 cases GvHD involved a single organ, in 24 cases 2, and in 6 cases 3 organs. Prior to MSC infusion 22 patients had received only high dose steroids, 12 patients received one cycle of pentostatin (1 mg/kg bodyweight for 3 days, Schmitt T. et al BMT, 2011: 46 580–585), while 13 received other conventional immunosuppressants. Patients received a median of 3 MSC infusions (range 1 to 8). No side effects were registered immediately after MSC infusion and no complications were lately referred as MSC-related. Overall, in 30 patients (63.8%) a clinical response of GvHD was registered. Thirteen of these patients (27.6%) had a complete response and 17 (36.1%) a partial response to treatment. Twenty-two of the 30 responding patients did not require further lines of immunosuppression after MSC infusion. Response was significantly more likely in patients exhibiting grade II GvHD versus those exhibiting more severe gradings (87.5% vs. 51.6%, p = 0.02) and in patients receiving MSC in a time interval of 30 days from the onset of GvHD (75.9% vs. 43.7%, p= 0.05). Current median follow up for this cohort is 200 days (range 30–1066). Responders show a significant lower transplant-related mortality (10.0% vs. 88.2%, p Measurements of plasmatic levels of IL2Ralpha, when comparing responders vs non-responders patients, showed a statistically significant difference in terms of fold decrease of the marker (p=0.027), corroborating clinical results. Similarly, a significant trend of fold decrease change (p=0.058) was observed when comparing responding patients receiving MSC within or after 30 days from the onset of the disease, in line with clinical results. Conclusions: This study confirms that human MSC prepared in academic cell therapy facilities may represent a safe and effective treatment of patients with steroid-refractory GvHD. Plasmatic inflammatory markers may help in evaluating and monitoring of clinical response. The sequential or combined administration of MSC and other immunosuppressants, such as pentostatin, is equally safe and feasible and deserves further investigation. We suggest to consider the use of MSC promptly, as early as possible, after steroid failure. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2012
35. Mesenchymal Stromal Cell-Derived PTX3 Promotes Wound Healing via Fibrin Remodeling
- Author
-
Andrea Biondi, Barbara Bottazzi, Fabio Pasqualini, Andrea Doni, Giovanna D'Amico, Manuela Nebuloni, Alberto Mantovani, Cecilia Garlanda, Claudia Cappuzzello, Erica Dander, Cappuzzello, C, Doni, A, Dander, E, Pasqualini, F, Nebuloni, M, Bottazzi, B, Mantovani, A, Biondi, A, Garlanda, C, and D'Amico, G
- Subjects
0301 basic medicine ,Stromal cell ,medicine.medical_treatment ,Mice, Inbred Strains ,Nerve Tissue Proteins ,Fibrin Remodeling ,Dermatology ,Mesenchymal Stem Cell Transplantation ,Biochemistry ,Fibrin ,Extracellular matrix ,Mice ,Random Allocation ,03 medical and health sciences ,Fibrinolysis ,medicine ,Animals ,Humans ,Molecular Biology ,Cells, Cultured ,PTX3 ,Skin ,Skin repair ,Wound Healing ,biology ,integumentary system ,Chemistry ,Mesenchymal stem cell ,Granulation tissue ,Mesenchymal Stem Cells ,Cell Biology ,Cell biology ,Radiography ,Disease Models, Animal ,C-Reactive Protein ,030104 developmental biology ,medicine.anatomical_structure ,Immunology ,biology.protein ,Wounds and Injuries ,Wound healing - Abstract
Although mesenchymal stromal cells (MSCs) can promote wound healing in different clinical settings, the underlying mechanism of MSC-mediated tissue repair has yet to be determined. Because a nonredundant role of pentraxin 3 (PTX3) in tissue repair and remodeling has been recently described, here we sought to determine whether MSC-derived PTX3 might play a role in wound healing. Using a murine model of skin repair, we found that Ptx3-deficient (Ptx3(-/-)) MSCs delayed wound closure and reduced granulation tissue formation compared with wt MSCs. At day 2, confocal microscopy revealed a dramatic reduction in green fluorescent protein (GFP)-expressing Ptx3(-/-) MSCs recruited to the wound, where they appeared to be not only poorly organized in bundles but also scattered in the extracellular matrix. These findings were further confirmed by quantitative biochemical analysis of GFP content in wound extracts. Furthermore, Ptx3(-/-) MSC-treated skins displayed increased levels of fibrin and lower levels of D-dimer, suggesting delayed fibrin-rich matrix remodeling compared with control skins. Consistently, both pericellular fibrinolysis and migration through fibrin were found to be severely affected in Ptx3(-/-) MSCs. Overall, our findings identify an essential role of MSC-derived PTX3 in wound repair underscoring the beneficial potential of MSC-based therapy in the management of intractable wounds.
- Full Text
- View/download PDF
36. Intraperitoneal adoptive transfer of mesenchymal stem cells enhances recovery from acid aspiration acute lung injury in mice
- Author
-
Tommaso Mauri, Vittoria Castiglioni, Giovanna D'Amico, Andrea Biondi, Alberto Mantovani, Andrea Doni, Cecilia Garlanda, Antonio Pesenti, Vanessa Zambelli, Giacomo Bellani, Claudia Cappuzzello, Marina Sironi, Erica Dander, Mauri, T, Zambelli, V, Cappuzzello, C, Bellani, G, Dander, E, Sironi, M, Castiglioni, V, Doni, A, Mantovani, A, Biondi, A, Garlanda, C, D'Amico, G, and Pesenti, A
- Subjects
0301 basic medicine ,Adoptive cell transfer ,Pathology ,medicine.medical_specialty ,Inflammation ,Stem cells ,Lung injury ,Critical Care and Intensive Care Medicine ,Pentraxin 3 ,Pulmonary function testing ,03 medical and health sciences ,0302 clinical medicine ,Fibrosis ,Acute lung injury ,medicine ,Stem cell ,Acute respiratory distress syndrome ,medicine.diagnostic_test ,business.industry ,Research ,Mesenchymal stem cell ,Acid aspiration syndrome ,respiratory system ,medicine.disease ,030104 developmental biology ,Bronchoalveolar lavage ,030228 respiratory system ,Tumor necrosis factor alpha ,medicine.symptom ,business - Abstract
Background Mesenchymal stem cells (MSCs) might act as fine-tuners of inflammation during acute lung injury. We assessed the effects of adoptive transfer of MSCs in acid aspiration acute lung injury and explored the role of long pentraxin PTX3. Methods We conducted a prospective experimental interventional study on wild-type (WT) and PTX3-deficient (PTX3−/−) mice. Acute lung injury was induced in WT and PTX3−/− mice by instillation of hydrochloric acid into the right bronchus. One hour later, animals received intraperitoneal sterile phosphate-buffered saline (PBS), WT-MSCs (1 × 106) or PTX3−/−-MSCs (1 × 106). Twenty-four hours after injury, we measured the effects of treatments on arterial blood gases, wet/dry lung weight (W/D), CT scan analysis of lung collapse, neutrophils, TNFα and CXCL1 in bronchoalveolar lavage, and plasma PTX3. d-dimer was assayed in 1 week and OH-proline in 2 weeks to track the fibrotic evolution. Results In 24 h, in comparison to PBS, WT-MSCs improved oxygenation and reduced W/D and alveolar collapse. These effects were associated with decreased concentrations of alveolar neutrophils and cytokines. WT-MSCs increased d-dimer concentration and decreased OH-proline levels, too. Treatment with PTX3−/−-MSCs ameliorated oxygenation, W/D, and alveolar TNFα, though to a lesser extent than WT-MSCs. PTX3−/−-MSCs did not improve lung collapse, neutrophil count, CXCL1, d-dimer, and OH-proline concentrations. The protective effects of WT-MSCs were dampened by lack of endogenous PTX3, too. Conclusions In acid aspiration acute lung injury, MSCs improve pulmonary function and limit fibrosis by fine-tuning inflammation. The role of PTX3 in determining MSCs’ effects might merit further scrutiny. Electronic supplementary material The online version of this article (doi:10.1186/s40635-017-0126-5) contains supplementary material, which is available to authorized users.
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.